Megakaryocyte Polyploidization and Proplatelet Formation in Low-Attachment Conditions

Alaina C Schlinker1, Mark T Duncan1, Teresa A DeLuca1

  • 1Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL.

Biochemical Engineering Journal
|April 19, 2016
PubMed

Insights

Generating platelets (PLTs) for transfusion involves megakaryocytes (MKs) forming proplatelets (proPLTs). Culturing MKs on non-adhesive surfaces then transferring them to adhesive surfaces can synchronize proplatelet formation and PLT generation.

Area of Science:

  • Biotechnology
  • Cell Biology
  • Hematology

Background:

  • * Platelets (PLTs) are crucial for hemostasis and are transfused to patients with thrombocytopenia.
  • * Current PLT production relies on donor blood, facing supply limitations.
  • * *In vitro* generation of PLTs from megakaryocytes (MKs) offers a potential alternative source.

Purpose of the Study:

  • * To investigate the impact of surface properties on MK polyploidization and proplatelet formation (PPF).
  • * To explore methods for synchronizing PPF and improving *in vitro* PLT generation.

Main Methods:

  • * Culturing a megakaryoblastic cell line and primary human MKs on surfaces with varying adhesive properties.
  • * Comparing polyploidization and PPF rates on low-attachment versus standard adhesive surfaces.
  • * Assessing PPF dynamics after transferring cells between surfaces.

Main Results:

  • * A megakaryoblastic cell line showed increased polyploidization and arrested PPF on a low-attachment surface.
  • * Primary human MKs exhibited reduced PPF on the low-attachment surface, with no change in ploidy.
  • * Both cell types demonstrated accelerated PPF upon transfer to an adhesive surface.

Conclusions:

  • * Surface properties significantly influence MK PPF, with non-adhesive surfaces potentially arresting the process.
  • * Pre-culture on non-adhesive surfaces followed by transfer to adhesive surfaces can synchronize PPF.
  • * This approach may enhance the efficiency and scalability of *in vitro* PLT generation for therapeutic use.